Get the Stockscreener App
1.10
1.79%
-0.02
Pre-market:
1.04
-0.06
-5.45%
Sutro Biopharma Inc stock is traded at $1.10, with a volume of 908.41K.
It is down -1.79% in the last 24 hours and up +21.08% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$1.12
Open:
$1.12
24h Volume:
908.41K
Relative Volume:
1.10
Market Cap:
$93.25M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-0.618
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
-5.17%
1M Performance:
+21.08%
6M Performance:
+0.00%
1Y Performance:
-69.01%
1-Day Range:
$1.01
$1.12
1-Week Range:
$1.01
$1.205
52-Week Range:
$0.5231
$4.60
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
1.10 | 94.95M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Applying big data sentiment scoring on Sutro Biopharma Inc.Market Movers & Advanced Swing Trade Entry Plans - newser.com
Can technical indicators confirm Sutro Biopharma Inc.’s reversalTrade Volume Summary & Growth Focused Stock Reports - newser.com
What earnings margins imply for Sutro Biopharma Inc. (S09) stockWeekly Profit Report & AI Powered Buy/Sell Recommendations - newser.com
Statistical indicators supporting Sutro Biopharma Inc.’s strengthBond Market & AI Powered Market Trend Analysis - newser.com
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference - The Manila Times
Sutro Biopharma, Inc. to Present Innovative Preclinical Data at World ADC Conference 2025 - Quiver Quantitative
Sutro (NASDAQ: STRO) to present preclinical data on dual-payload ADCs at World ADC - Stock Titan
What candlestick patterns are forming on Sutro Biopharma Inc.Jobs Report & High Return Trade Guides - newser.com
Analyzing Sutro Biopharma Inc. with risk reward ratio chartsMarket Performance Summary & Long-Term Capital Growth Strategies - newser.com
Can Sutro Biopharma Inc. recover in the next quarterGap Down & Comprehensive Market Scan Insights - newser.com
Is it too late to sell Sutro Biopharma Inc.Weekly Trading Summary & Real-Time Volume Analysis - newser.com
Published on: 2025-11-02 22:36:42 - newser.com
Is Sutro Biopharma Inc. stock a safe haven assetDollar Strength & Daily Profit Focused Screening - newser.com
Is Sutro Biopharma Inc. stock a buy on dipsDividend Hike & AI Enhanced Trade Execution Alerts - newser.com
Can Sutro Biopharma Inc. (S09) stock deliver strong annual returnsWeekly Trade Review & High Conviction Buy Zone Alerts - newser.com
Applying Wyckoff theory to Sutro Biopharma Inc. stockDividend Hike & Smart Money Movement Alerts - newser.com
Published on: 2025-11-01 09:13:17 - newser.com
Volatility clustering patterns for Sutro Biopharma Inc.Index Update & Long-Term Growth Plans - newser.com
How to monitor Sutro Biopharma Inc. with trend dashboards2025 Valuation Update & Precise Buy Zone Tips - newser.com
How buybacks impact Sutro Biopharma Inc. stock valuePortfolio Update Report & Technical Confirmation Alerts - newser.com
Can Sutro Biopharma Inc. stock sustain revenue growthMarket Performance Recap & Smart Swing Trading Alerts - newser.com
Does Sutro Biopharma Inc. show high probability of rebound2025 Trade Ideas & Reliable Intraday Trade Alerts - newser.com
Identifying reversal signals in Sutro Biopharma Inc.Market Performance Recap & Real-Time Sentiment Analysis - newser.com
Why Sutro Biopharma Inc. stock is considered a top pick2025 Earnings Surprises & Technical Pattern Recognition Alerts - newser.com
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chow Gregory K. | CFO |
Oct 15 '25 |
Buy |
0.81 |
19,750 |
15,998 |
19,750 |
| Chung Jane | Chief Executive Officer |
Oct 15 '25 |
Buy |
0.80 |
12,500 |
10,011 |
122,850 |
| MATSUI CONNIE | Director |
Oct 15 '25 |
Buy |
0.80 |
50,000 |
39,950 |
50,000 |
| Pauling David | Chief Admin. Ofcr. & GC |
Oct 15 '25 |
Buy |
0.80 |
12,504 |
9,993 |
71,737 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Sep 18 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
68,249 |
| Leyman Barbara | Chief Business Officer |
Jul 08 '25 |
Option Exercise |
0.00 |
25,000 |
0 |
25,000 |
| Chung Jane | Chief Executive Officer |
Aug 09 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
117,058 |
| ALBINI EDWARD C | CFO AND SECRETARY |
May 15 '25 |
Option Exercise |
0.00 |
44,719 |
0 |
176,800 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
37,849 |
0 |
133,282 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
54,580 |
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):